Novo, Nordisk

Novo Nordisk Payouts, Pediatric Data and an AI Pact Fill a Heavy November Calendar

Published on 11/22/2026 at 19:40 | Editorial boerse-global.de
Denmark's compensation board awarded DKK 15M to 31 people over NAION after Wegovy or Ozempic; Novo shares fell 3.0% as pipeline news rolled in.
Novo, Nordisk, Payouts, Pediatric, Data, Pact, Fill, Heavy, Calendar, Denmarks Illustration mit AI erstellt.

Denmark's patient compensation board has awarded a combined DKK 15 million to 31 people who reported the eye condition NAION after taking Wegovy or Ozempic, according to figures current as of 18 November. The body turned down 29 applications, while 34 cases remain unresolved.

Novo Nordisk shares slipped 3.0% on Friday as the claims tally circulated.

The NAION decisions landed alongside a dense stretch of pipeline news. On 13 November the European Commission granted marketing authorisation for Frehemgo as routine prophylaxis against bleeding in adults and children with haemophilia A, with or without inhibitors. Novo Nordisk expects the first European launches next year. That same day the company filed with both the FDA and the EMA for Etavopivat, a once-daily candidate for adolescents and adults with sickle cell disease.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Wegovy clears the 10% BMI threshold in young children

Pediatric obesity data arrived on 16 November from the Phase 3 STEP Young trial, which enrolled children aged six to under twelve. Nearly 80% of those treated with Wegovy saw their body-mass index fall by at least 10%, a bar no child in the placebo arm reached. By week 68, BMI across the semaglutide arm had dropped 13.5%, against a 2.7% increase under placebo.

CagriSema, still under review, produced its own set of numbers on 14 November from the Phase 3 REDEFINE 9 study. Participants on the two lower doses lost an average of 20.7% and 21.0% of body weight through 68 weeks, compared with 2.0% on placebo. Those figures assume every patient stayed on treatment for the full period.

nference tie-up pairs trial data with an AI health network

Separately, Novo Nordisk and nference will jointly investigate cardiovascular and metabolic disease as well as healthy ageing. The collaboration, announced by nference on 18 November, is designed to link Novo Nordisk's clinical trial data with nference's artificial intelligence platform and health data network.

Ad

Novo Nordisk Stock: New Analysis - 22 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70544770 |